oral glp-1 drugs in development The Growing Impact of GLP-1s on Obesity Treatment Comparing Ozempic, Wegovy and Other

by TNG Founding Member Jennifer Dowd

In a recent clinical study, individuals with heart failure and preserved ejection fraction who received weekly semaglutide injections (2.4 mg) for 52 weeks experienced substantially improved symptoms and physical function compared to the placebo group 9

The choice among the different members of this class depends on our clinical judgement considering the cardiovascular risk assessment, the GIT tolerance, the finance and the compliance of our patient

Results The numbers of QALYs gained from 2020 to 2040 with increased SGLT2i and GLP-1 RA use in the total population ( n =1.1 million in 2020

[DOI] [PMC free article] [PubMed] [Google Scholar] 159.Reshef L., Olswang Y., Cassuto H., Blum B., Croniger C.M., Kalhan S.C., Tilghman S.M., Hanson R.W